CASI Pharma (CASI) Misses Q3 EPS by 2c

CASI Pharma (NASDAQ: CASI) reported Q3 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $7.54 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• DHT Holdings Q2 TCE earnings estimated at $126,700 per day
• Morgan Stanley Downgrades Tryg A/S (TRYG:DC) (TGVSF) to Underweight